logo

LYEL

Lyell Immunopharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
Revenue Plunges
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About LYEL

Lyell Immunopharma, Inc.

A clinical‑stage T-cell reprogramming company that develops curative cell therapies for solid tumors

Biological Technology
Invalid Date
06/17/2021
NASDAQ Stock Exchange
300
12-31
Common stock
201 Haskins Way, South San Francisco, California 94080
--
Lyell Immunopharma, Inc., was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy company that is expected to enter pivotal trials in 2025 and advance a proprietary next-generation pipeline of autologous chimeric antigen receptor T cell product candidates for patients with hematological malignancies and solid tumors. The company is pioneering new methods aimed at generating T cells that drive durable clinical responses. The patient's living cells are the starting point for the company's investigational CAR T cell therapy, which the company enhances with innovative CAR structures, technologies and manufacturing protocols.

Company Financials

EPS

LYEL has released its 2024 Q4 earnings. EPS was reported at -0.71, versus the expected -0.13, missing expectations. The chart below visualizes how LYEL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LYEL has released its 2024 Q4 earnings report, with revenue of 11.00K, reflecting a YoY change of -15.38%, and net profit of -191.94M, showing a YoY change of -262.62%. The Sankey diagram below clearly presents LYEL’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime